A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Inclusion Criteria: * Participants enrolled in a Roche-sponsored alectinib trial who are experiencing a clinical benefit from alectinib or crizotinib treatment at the time of discontinuation from the parent trial and for whom a switch to commercial supply is not feasible * Collected study termination data, including efficacy and safety data, as required by the parent study on the electronic Case Report Form (eCRF) * For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 3 months after the last dose of study drug * For men: agreement to remain abstinent or use a contraceptive method that results in a failure rate of \< 1% per year during the treatment period and for at least 3 months after the last dose of study drug. Exclusion Criteria: * Evidence of lack of clinical benefit in parent trial during the screening phase of this rollover study * Permanent discontinuation of alectinib or crizotinib for any reason during the parent study or before first dose of study drug in the rollover study * Evidence of an adverse event for which the parent protocol stipulates permanent discontinuation * Pregnant or breastfeeding women * Ongoing serious adverse event that has not resolved to baseline level or Grade ≤1 prior to first dose…